Does bispecific use impact T-cell harvesting for other manufactured T-cell directed therapies?

So what about the impact on manufacturing for Car-T? this is another area of active investigation. What we now know so far is, you know, the single best therapy, myeloma cilta-cel, which has a remission of three years. If somebody got prior therapy directed against the same antigen BCmA, that remission drops to about five months.

If they had prior BCmA bispecific and maybe like 7 to 9 months if they had a prior antibody drug conjugate. Why is that? You know, we don't know how much of that is the target versus the mechanism. It's probably a little bit of both. So talquetamab targeting GPRC5D might be more reasonable to do prior to doing a Car-T.

But if I had my druthers, because we don't know about the T-cell exhaustion, if you can think about two patient scenarios, let's say I want to take somebody to cilta-cel or CARVYKTI, but I don't have a slot right now. Patient one gets the T-cells collected and then gets talquetamab and then goes to cilta-cel down the road.

Patient two gets talquetamab and when it stops working, collects for cilta-cel and goes to CARVYKTI. I would prefer to do the patient one strategy, because we don't know the impact of using a bispecific till it fails, and then trying to get those T-cells to now expand and do genetic modifications for Car-T. So I think if you're going to do planning for now, if you have the ability try to collect for the Car-T, but then once you've collected, it may be much more, you know, much less concerned about doing a bispecific in the interval time.